Drug ID: 1d00000141
Drug Name: Axitinib Tablets
Generic Names: Inlyta
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: The initial recommended dose is 5mg/day.
Recommended In: This medication is a kinase inhibitor, prescribed for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. It blocks the action of an abnormal protein, which helps in cancer cells multiplication.
Directions For Use: It comes as a tablet to take by mouth, with or without food.
Storage: Store it at room temperature (20°C to 25°C).
Dosage Forms: Tablet
Side Effects: Most Common - Diarrhea, high blood pressure, fatigue, decreased appetite, nausea, loss of voice, hand-foot syndrome (palmar-plantar erythrodysesthesia), weight loss, vomiting, weakness and constipation.
Miscellaneous - Hypothyroidism, cough, mucosal inflammation, joint pain, mouth ulcer, difficulty in breathing, abdominal pain, headache, pain in extremity, rash, protein in urine, taste disorder, indigestion, difficulty in swallowing, itching, hair loss, redness.
In Case of Overdose: In cases of suspected overdose, Axitinib should be withheld and supportive care instituted.
Avoid If: Caution should be exercised in patients with history of high blood pressure, thyroid problem, liver impairment, blood clot events, bleeding problems, unhealed wound, who are taking other medications, any allergy, during pregnancy and breastfeeding.
Avoid drinking grapefruit juice or eat grapefruit while taking this medication.
Drug Interaction: CYP3A4/5 Inhibitors
Co-administration of ketoconazole, a strong inhibitor of CYP3A4/5, increased the plasma exposure of axitinib in healthy volunteers. Co-administration of axitinib with strong CYP3A4/5 inhibitors should be avoided. Grapefruit or grapefruit juice may also increase axitinib plasma concentrations and should be avoided. Selection of concomitant medication with no or minimal CYP3A4/5 inhibition potential is recommended. If a strong CYP3A4/5 inhibitor must be co-administered, the axitinib dose should be reduced.
Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of axitinib in healthy volunteers. Co-administration of axitinib with strong CYP3A4/5 inducers (e.g., rifampin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarbital, and St. John's wort) should be avoided. Selection of concomitant medication with no or minimal CYP3A4/5 induction potential is recommended. Moderate CYP3A4/5 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, and nafcillin) may also reduce the plasma exposure of axitinib and should be avoided if possible.